ProCE Banner Activity

CE / CME

“How Do We Practically Do This?” Expert Guidance and Interactive Practice on SGLT2i Integration Across the Spectrum of Heart Failure

Video

This on-demand webcast offers expert guidance on the integration of SGLT2 inhibitors in the management of heart failure across its various stages. 

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Nurses: 1.50 Nursing contact hours

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Released: December 11, 2024

Expiration: December 10, 2025

Share

Faculty

Javed Butler

Javed Butler, MD, MPH, MBA

President of the Baylor Scott and White Research Institute
Senior Vice President for the Baylor Scott and White Health
Maxwell A. and Gayle H. Clampitt Endowed Chair
Dallas, Texas
Distinguished Professor of Medicine
University of Mississippi
Jackson, Mississippi

Lauren S. Eyadiel

Lauren S. Eyadiel, MS, MMS, PA-C, SLP, FHFSA

Assistant Professor
Heart Failure-Certified
Department of PA Studies
Wake Forest University School of Medicine
Advanced Heart Failur, Heart Transplant, and Mechanical Circulatory Support
Atrium Health Wake Forest Baptist
Winston Salem, North Carolina

Ty J. Gluckman

Ty J. Gluckman, MD, MHA

Medical Director
Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System
Portland, Oregon

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company

Target Audience

This activity is intended for HCPs who care for patients with heart failure, including cardiology physicians, nurse practitioners, and physician associates.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Heart Failure.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Summarize the latest clinical trial data and real-world evidence in support of the safety and efficacy of SGLT2 inhibition as foundational therapy for patients across the HF spectrum

  • Develop personalized approaches for the integration of SGLT2i into treatment plans for patients with HF across the spectrum of LVEF

  • Apply strategies for effective patient counseling that address the benefits and adverse effects of SGLT2 inhibition in patients with HF

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Javed Butler, MD, MPH, MBA

President of the Baylor Scott and White Research Institute
Senior Vice President for the Baylor Scott and White Health
Maxwell A. and Gayle H. Clampitt Endowed Chair
Dallas, Texas
Distinguished Professor of Medicine
University of Mississippi
Jackson, Mississippi

Javed Butler, MD, MPH, MBA: consultant/advisor/speaker: Abbott, American Regent, Amgen Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardiocell, Cardior, CSL Bearing, CVRx, Cytokinetics, Daxor, Edwards, Element Science, Faraday, Foundry, G3P, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Janssen, Levator, Lexicon, Lilly, LivaNova, Medtronics, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Roche, Salamandra, Salubris, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor, Zoll.

Lauren S. Eyadiel, MS, MMS, PA-C, SLP, FHFSA

Assistant Professor
Heart Failure-Certified
Department of PA Studies
Wake Forest University School of Medicine
Advanced Heart Failur, Heart Transplant, and Mechanical Circulatory Support
Atrium Health Wake Forest Baptist
Winston Salem, North Carolina

Lauren S. Eyadiel, MS, MMS, PA-C, SLP, FHFSA: consultant/advisor/speaker: Bayer.

Ty J. Gluckman, MD, MHA

Medical Director
Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System
Portland, Oregon

Ty J. Gluckman, MD, MHA has no relevant financial relationships to disclose.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 11, 2024, through December 10, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.

Physician Associate Continuing Medical Education 

AAPA CME Accreditation - AAPA

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until December 10, 2025. PAs should only claim credit commensurate with the extent of their participation.

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.